Are all statins the same?: Focus on the efficacy and tolerability of pitavastatin

American Journal of Cardiovascular Drugs

Volumn 11, Issue 2, 2011, Pages 93-107

  Da Silva, Pedro Marques ^a  

^a EPE   (Portugal)

Author keywords

diabetes mellitus; HMG CoA reductase inhibitors; hypercholesterolemia; hyperlipidemia; pitavstatin; statins

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL; CREATINE KINASE; CYTOCHROME P450; CYTOCHROME P450 3A4; ERYTHROMYCIN; EZETIMIBE; FENOFIBRATE; FENOFIBRIC ACID; GEMFIBROZIL; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ICOSAPENTAENOIC ACID; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PITAVASTATIN; PLACEBO; PRAVASTATIN; RIFAMPICIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; WARFARIN;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BACKACHE; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); CONSTIPATION; DIABETIC PATIENT; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXCRETION; DRUG INTERACTION; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ENZYME BLOOD LEVEL; GASTROINTESTINAL DISEASE; GLUCOSE METABOLISM; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INDIGESTION; INFLAMMATION; KIDNEY FUNCTION; METABOLIC SYNDROME X; MULTICENTER STUDY (TOPIC); MUSCULOSKELETAL DISEASE; MYALGIA; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PAIN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHABDOMYOLYSIS; RHINOPHARYNGITIS; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; BLOOD GLUCOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; QUINOLINES; TREATMENT OUTCOME;

EID: 79953238469     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.2165/11591190-000000000-00000     Document Type: Review

References (98)

1. European Heart Network. European Cardiovascular Disease Statistics. 2008 [online]. Available from URL: Http://www.ehnheart.org/cdv-statistics.html [Accessed 2010 Nov 10]
2. European Heart Network. European Cardiovascular Disease Statistics 2008. 2008 [online]. Available from URL: Http://www.ehnheart.org/component/ downloads/downloads/683.html [Accessed 2010 Nov 10]
3. Kuulasmaa K, Tunstall-Pedoe H, Dobson A, et al. Estimation of contribution of changes in classic risk factors to trends in coronary-event rates across the WHOMONICAProject populations. Lancet 2000 Feb 26; 355 (9205): 675-87 (Pubitemid 30107623)
4. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004 Sep 11-17; 364 (9438): 937-52 (Pubitemid 39208455)
5. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). EurHeart J 2007 Oct; 28 (19): 2375-414 (Pubitemid 47542237)
6. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospectivemeta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005 Oct 8; 366 (9493): 1267-78
7. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 2006 Apr 5; 295 (13): 1556-65
8. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 2004 Mar 3; 291 (9): 1071-80 (Pubitemid 38541684)
9. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: Ameta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010 Nov 13; 376 (9753): 1670-81
10. Kowa Pharmaceuticals America Inc. Livalo (pitavastatin) tablets: Full prescribing information. 2009 [online].Available from URL:http://www.livalorx. com/documents/LIVALOpitavastatinprescribinginformationV1-220100131.pdf [Accessed 2010 Nov 8]
11. Aoki T, Nishimura H, Nakagawa S, et al. Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneimittelforsch 1997 Aug; 47 (8): 904-9
12. Morikawa S, UmetaniM, Nakagawa S, et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb 2000; 7 (3): 138-44
13. Suzuki H, Aoki T, Tamaki T, et al. Hypolipidemic effect of NK-104, a potent HMG-CoAreductase inhibitor, in guinea pigs.Atherosclerosis 1999 Oct; 146 (2): 259-70 (Pubitemid 29418057)
14. Nakagawa S, Tanabe S, Tamaki T, et al. Effect of NK-104, an HMG-CoA reductase inhibitor on lipid metabolism in HepG2 cells. Jpn Pharmacol Ther 2001; 29 (1): 51-7 (Pubitemid 32373740)
15. Yanagita T, Hara E, Yotsumoto H, et al. NK-104, a potent new 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibitor, enhances posttranslational catabolism of apolipoprotein B-100 and inhibits secretion of apolipoprotein B-100 and triacylglycerols from HepG2 cells. Curr Therap Res 1999; 60: 423-34 (Pubitemid 29402500)
16. Maejima T, Yamazaki H, Aoki T, et al. Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem Biophys Res Commun 2004 Nov 12; 324 (2): 835-9 (Pubitemid 39345591)
17. Kibayashi E, Urakaze M, Kobashi C, et al. Inhibitory effect of pitavastatin (NK-104) on the C-reactive-protein-induced interleukin-8 production in human aortic endothelial cells. Clin Sci (Lond) 2005 Jun; 108 (6): 515-21 (Pubitemid 40827559)
18. Hiraoka M, Nitta N, Nagai M, et al. MCP-1-induced enhancement of THP-1 adhesion to vascular endothelium was modulated by HMG-CoA reductase inhibitor through RhoA GTPase-, but not ERK1/2-dependent pathway. Life Sci 2004 Jul 30; 75 (11): 1333-41 (Pubitemid 38845032)
19. Morikawa S, Takabe W, Mataki C, et al. Global analysis of RNA expression profile in human vascular cells treated with statins. J Atheroscler Thromb 2004; 11 (2): 62-72
20. Markle RA, Han J, Summers BD, et al. Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells. J Cell Biochem 2003 Sep 1; 90 (1): 23-32 (Pubitemid 37052306)
21. Morikawa S, TakabeW,Mataki C, et al. The effect of statins on mRNA levels of genes related to inflammation, coagulation, and vascular constriction in HUVEC (human umbilical vein endothelial cells). J Atheroscler Thromb 2002; 9 (4): 178-83
22. Masamura K, Oida K, Kanehara H, et al. Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family. Arterioscler Thromb Vasc Biol 2003 Mar 1; 23 (3): 512-7 (Pubitemid 36337231)
23. Suzuki H, Kobayashi H, Sato F, et al. Plaque-stabilizing effect of pitavastatin in Watanabe heritable hyperlipidemic (WHHL) rabbits. J Atheroscler Thromb 2003; 10 (2): 109-16
24. Maeda K, Yasunari K, Sato EF, et al. Enhanced oxidative stress in neutrophils from hyperlipidemic guinea pig. Atherosclerosis 2005 Jul; 181 (1): 87-92 (Pubitemid 40804697)
25. Hayashi T, Rani PJ, Fukatsu A, et al. A new HMG-CoA reductase inhibitor, pitavastatin remarkably retards the progression of high cholesterol induced atherosclerosis in rabbits. Atherosclerosis 2004 Oct; 176 (2): 255-63 (Pubitemid 39369514)
26. Wang J, Tokoro T, Matsui K, et al. Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-AKT pathway in endothelial cells. Life Sci 2005 Mar 25; 76 (19): 2257-68 (Pubitemid 40283650)
27. Kuzuya M, Cheng XW, Sasaki T, et al. Pitavastatin, a 3-hydroxy-3- methylglutaryl- coenzyme A reductase inhibitor, blocks vascular smooth muscle cell populated-collagen lattice contraction. J Cardiovasc Pharmacol 2004 Jun; 43 (6): 808-14 (Pubitemid 38679602)
28. Katsumoto M, Shingu T, Kuwashima R, et al. Biphasic effect of HMG-CoA reductase inhibitor, pitavastatin, on vascular endothelial cells and angiogenesis. Circ J 2005 Dec; 69 (12): 1547-55 (Pubitemid 41743974)
29. Nakano K, Egashira K. Pitavastatin has most potent pro-healing effects on endothelial cells and inhibitory effects on proliferation of vascular smooth muscle cells: A potential treatment strategy for drug-eluting stents [general presentation No. 21]. 41st annual Scientific Meeting of the Japan Atherosclerosis Society; 2009 17-18 July; Yamaguchi
30. Nicholson AC, Hajjar DP, Zhou X, et al. Anti-adipogenic action of pitavastatin occurs through coordinate regulation of PPAR-gamma and Pref-1 expression. Br J Pharmacol 2007; 151: 807-15 (Pubitemid 47075310)
31. FujinoH, Kojima J,Yamada Y, et al. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (4): Interspecies variation in laboratory animals and humans. Xenobio Metabol Dispos 1999; 14: 79-91
32. Kimata H, Fujino H, Koide T, et al. Studies on the metabolic fate of NK-104, a new inhibitor of HMG-CoA reductase (1): Absorption, distribution, metabolism and excretion in rats. Xenobio Metabol Dispos 1998; 13: 484-98
33. Nakaya N, Uebaba K, Takebe M, et al. A phase 1 clinical study of a novel HMG-CoA reductase inhibitor, NK-104 (pitavastatin): Results of single and 7-day repeated oral administration studies in healthy adult male volunteers. J Clin Ther Med 2001; 17: 741-66
34. Kojima J, Ohshima T, Yoneda M, et al. Effect of biliary excretion on the pharmacokinetics of pitavastatin in dogs. Xenobio Metabol Dispos 2001; 16: 497-502
35. Ando H, Tsuruoka S, Yanagihara H, et al. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol 2005 Nov; 60 (5): 494-7
36. Nakagawa S, Hounslow N. Pitavastatin is not subject to clinically relevant pharmacokinetic interactions when administered with CYP3A4 inhibitors in healthy volunteers [abstract P5413]. ESC Congress 2009: Annual Congress of the European Society of Cardiology; 2009; Barcelona
37. Hirano M, Maeda K, Shitara Y, et al. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 2004 Oct; 311 (1): 139-46 (Pubitemid 39287793)
38. Shimada S, Fujino H, Morikawa T, et al. Uptake mechanism of pitavastatin, a new inhibitor of HMG-CoA reductase, in rat hepatocytes. Drug Metab Pharmacokinet 2003; 18 (4): 245-51
39. Hasunuma T, Nakamura M, Yachi T, et al. The drug-drug interactions of pitavastatin (NK-104), a novel HMG-CoA reductase inhibitor and cyclosporine. J Clin Ther Med 2003; 19 (4): 381-9
40. ChoiCI, Bae JW, LeeHI, et al. Effects of SLCO1B1 genetic polymorphism on the pharmacokinetics of pitavastatin in Koreans [abstract]. 14th Congress of the European Hematology Association, 2009; Berlin. Haematologica; 2009: 79
41. Chung JY, Cho JY, Yu KS, et al. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 2005 Oct; 78 (4): 342-50
42. Deng JW, Song IS, ShinHJ, et al. The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: The contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics 2008 May; 18 (5): 424-33 (Pubitemid 351535943)
43. Ieiri I, Suwannakul S, Maeda K, et al. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 2007 Nov; 82 (5): 541-7 (Pubitemid 47622520)
44. Wen J, Xiong Y. OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers. J Clin Pharm Ther 2010 Feb; 35 (1): 99-104
45. Hui CK, Cheung BM, Lau GK. Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. Br J Clin Pharmacol 2005 Mar; 59 (3): 291-7 (Pubitemid 40388083)
46. Nakaya N, Tateno M, Nakamura T, et al. Pharmacokinetics of repeated dose NK-104 (pitavastatin) in healthy elderly and non-elderly volunteers. J Clin Therap Med 2001; 17 (6): 957-70
47. Budinski D, Arneson V, Hounslow N, et al. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin Lipidol 2009; 4 (3): 291-302
48. Koshiyama H, Taniguchi A, Tanaka K, et al. Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigators. J Atheroscler Thromb 2008 Dec; 15 (6): 345-50
49. Lee SH, Chung N, Kwan J, et al. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: An 8-week, multicenter, randomized, openlabel, dose-titration study in Korean patients with hypercholesterolemia. Clin Ther 2007 Nov; 29 (11): 2365-73 (Pubitemid 350298122)
50. Ose L, Budinski D, Hounslow N, et al. Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr Med Res Opin 2009 Nov; 25 (11): 2755-64
51. Park S, Kang HJ, Rim SJ, et al.A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia. Clin Ther 2005 Jul; 27 (7): 1074-82 (Pubitemid 41262465)
52. Saito Y, Yamada N, Teramoto T, et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis 2002 Jun; 162 (2): 373-9 (Pubitemid 34457943)
53. Sansanayudh N, Wongwiwatthananukit S, Putwai P, et al. Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia. Ann Pharmacother 2010 Mar; 44 (3): 415-23
54. Yokote K, Bujo H, Hanaoka H, et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: Collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis 2008 Dec; 201 (2): 345-52
55. Yoshitomi Y, Ishii T, Kaneki M, et al. Efficacy of a low dose of pitavastatin compared with atorvastatin in primary hyperlipidemia: Results of a 12-week, open label study. J Atheroscler Thromb 2006 Apr; 13 (2): 108-13
56. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001 May 16; 285 (19): 2486-97
57. European Atherosclerosis Society. The recognition and management of hyperlipidaemia in adults: A policy statement of the European Atherosclerosis Society. Eur Heart J 1988 May; 9 (5): 571-600
58. Fukutomi T, Takeda Y, Suzuki S, et al. High density lipoprotein cholesterol and apolipoprotein A-I are persistently elevated during long-term treatment with pitavastatin, a new HMG-CoA reductase inhibitor. Int J Cardiol 2010 Jun 11; 141 (3): 320-2
59. Noji Y, Higashikata T, Inazu A, et al. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis 2002 Jul; 163 (1): 157-64 (Pubitemid 34615738)
60. Ose L, Budinski D, Hounslow N, et al. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis 2010 May; 210 (1): 202-8
61. Kurihara Y, Douzono T,KawakitaK, et al. A large-scale, long-term, prospective post-marketing surveillance of pitavastatin (LIVALO-tablet): LIVALO Effectiveness and Safety (LIVES) study. Jpn Pharmacol Ther 2008; 36 (8): 709-31
62. Teramoto T, Shimano H, Yokote K, et al. Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia. J Atheroscler Thromb 2009 Oct; 16 (5): 654-61
63. Kajinami K, Koizumi J, Ueda K, et al. Effects of NK-104, a new hydroxymethylglutaryl- coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Hokuriku NK-104 Study Group. Am J Cardiol 2000 Jan 15; 85 (2): 178-83 (Pubitemid 30026098)
64. Kawano M, Nagasaka S, Yagyu H, et al. Pitavastatin decreases plasma prebeta1- HDL concentration and might promote its disappearance rate in hypercholesterolemic patients. J Atheroscler Thromb 2008 Feb; 15 (1): 41-6
65. Majima T, Shimatsu A, Komatsu Y, et al. Short-term effects of pitavastatin on biochemical markers of bone turnover in patients with hypercholesterolemia. Intern Med 2007; 46 (24): 1967-73
66. Matsumoto T, Fujita M, Sawamura T, et al. Pitavastatin reduces lectin-like oxidized low-density lipoprotein receptor-1 ligands in hypercholesterolemic humans. Lipids 2010 Apr; 45 (4): 329-35
67. Mizuguchi Y, Oishi Y, Miyoshi H, et al. Impact of statin therapy on left ventricular function and carotid arterial stiffness in patients with hypercholesterolemia. Circ J 2008 Apr; 72 (4): 538-44 (Pubitemid 351679403)
68. Ohbayashi H, Miyazawa C, Miyamoto K, et al. Pitavastatin improves plasma pentraxin 3 and arterial stiffness in atherosclerotic patients with hypercholesterolemia. J Atheroscler Thromb 2009 Aug; 16 (4): 490-500
69. Sakabe K, Fukuda N, Fukuda Y, et al. Comparisons of short- and intermediateterm effects of pitavastatin versus atorvastatin on lipid profiles, fibrinolytic parameter, and endothelial function. Int J Cardiol 2008 Mar 28; 125 (1): 136-8 (Pubitemid 351305417)
70. Inami N, Nomura S, Shouzu A, et al. Effects of pitavastatin on adiponectin in patients with hyperlipidemia. Pathophysiol Haemost Thromb 2007; 36 (1): 1-8 (Pubitemid 351373317)
71. Kawai T, TokuiM, Funae O, et al. Efficacy of pitavastatin, a new HMG-CoA reductase inhibitor, on lipid and glucose metabolism in patients with type 2 diabetes. Diabetes Care 2005 Dec; 28 (12): 2980-1 (Pubitemid 43942938)
72. Monden T, Matsumura M, Kawagoe Y, et al. An open-label, crossover study of the effects of rosuvastatin and pitavastatin on lipid profiles and inflammation markers in patients with diabetes [abstract P2-325]. 90th Annual Meeting of the Endocrine Society; 2008; San Francisco (CA)
73. Motomura T, Okamoto M, Kitamura T, et al. Effects of pitavastatin on serum lipids and high sensitivity C-reactive protein in type 2 diabetic patients. J Atheroscler Thromb 2009 Oct; 16 (5): 546-52
74. Nomura S, Inami N, Shouzu A, et al. The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients. Platelets 2009 Feb; 20 (1): 16-22
75. Sasaki J, Ikeda Y, Kuribayashi T, et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther 2008 Jun; 30 (6): 1089-101 (Pubitemid 351978115)
76. Sone H, Takahashi A, Shimano H, et al. HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes. Life Sci 2002 Oct 4; 71 (20): 2403-12 (Pubitemid 35264612)
77. Tokuno A, Hirano T, Hayashi T, et al. The effects of statin and fibrate on lowering small dense LDL-cholesterol in hyperlipidemic patients with type 2 diabetes. J Atheroscler Thromb 2007 Jun; 14 (3): 128-32
78. Yamakawa T, Takano T, Tanaka S, et al. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb 2008 Oct; 15 (5): 269-75
79. Yokote K, Saito Y. Influence of statins on glucose tolerance in patients with type 2 diabetes mellitus: Subanalysis of the collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). J Atheroscler Thromb 2009 Jun; 16 (3): 297-8
80. Stender S, HounslowN. Robust efficacy of pitavastatin and comparable safety to pravastatin. 15th International Symposium on Atherosclerosis; 2009; Boston (MA)
81. Nakamura T, Sato E, Fujiwara N, et al. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. Pharmacol Res 2010 Jan; 61 (1): 58-61
82. Ono K, Kawasaki M, Tanaka R, et al. Integrated backscatter and intimamedia thickness of the thoracic aorta evaluated by transesophageal echocardiography in hypercholesterolemic patients: Effect of pitavastatin therapy. Ultrasound Med Biol 2009 Feb; 35 (2): 193-200
83. Takashima H, Ozaki Y, Yasukawa T, et al. Impact of lipid-lowering therapy with pitavastatin, a new HMG-CoA reductase inhibitor, on regression of coronary atherosclerotic plaque. Circ J 2007 Nov; 71 (11): 1678-84 (Pubitemid 350240085)
84. Hiro T, Kimura T, Morimoto T, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: A multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 2009 Jul 21; 54 (4): 293-302
85. Toi T, Taguchi I, Yoneda S, et al. Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque: Comparison with atorvastatin. Circ J 2009 Aug; 73 (8): 1466-72
86. Kojima T, Ono K, Tanaka R, et al. Effect of statin therapy on the thoracic aorta in hypercholerolemic patients evaluated by integrated backscatter and wall thickness with transesophageal echocardiography [abstract P4933]. ESC Congress 2008: Annual Congress of the European Society of Cardiology; 2008; Munich
87. Nakamura T, Obata JE, Kitta Y, et al. Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome. J Cardiovasc Pharmacol 2008 Apr; 51 (4): 365-71 (Pubitemid 351572235)
88. Miyashita Y, Endo K, Saiki A, et al. Effects of pitavastatin, a 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibitor, on cardio-ankle vascular index in type 2 diabetic patients. J Atheroscler Thromb 2009 Oct; 16 (5): 539-45
89. Nakamura T, Sugaya T, Kawagoe Y, et al. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care 2005 Nov; 28 (11): 2728-32 (Pubitemid 43951167)
90. Yoshida O, Kondo T, Kureishi-Bando Y, et al. Pitavastatin, an HMG-CoA reductase inhibitor, ameliorates endothelial function in chronic smokers. Circ J 2010 Jan; 74 (1): 195-202
91. Aoyagi T, Nakamura F, Tomaru T, et al. Beneficial effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardiac function in ischemic and nonischemic heart failure. IntHeart J 2008 Jan; 49 (1): 49-58 (Pubitemid 351663723)
92. Suzuki Y, Kaneko J, Ito H. Pitavastatin may improve cardiac function [abstract]. 69th Annual Scientific Meeting of the Japanese Circulation Society, March 19-21, 2005; Yokohama. Circulation Journal 2005 (69): 6
93. Nakamura T, Sugaya T, Kawagoe Y, et al. Effect of pitavastatin on urinary liver-type fatty-acid-binding protein in patients with nondiabetic mild chronic kidney disease. Am J Nephrol 2006; 26 (1): 82-6
94. Kimura K, Shimano H, Yokote K, et al. Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease: Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) Study. J Atheroscler Thromb Jun 30; 17 (6): 601-9
95. Hayashi T, Yokote K, Saito Y, et al. Pitavastatin: Efficacy and safety in intensive lipid lowering. Expert Opin Pharmacother 2007 Oct; 8 (14): 2315-27 (Pubitemid 350001592)
96. Saito Y. Critical appraisal of the role of pitavastatin in treating dyslipidemias and achieving lipid goals. Vasc Health Risk Manag 2009; 5: 921-36
97. SaikiA,Murano T, Watanabe F, et al. Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes. JAtheroscler Thromb 2005; 12 (3): 163-8
98. Hanyu O, Miida T, Obayashi K, et al. Lipoprotein lipase (LPL) mass in preheparin serum reflects insulin sensitivity. Atherosclerosis 2004 Jun; 174 (2): 385-90 (Pubitemid 38597098)